🟢 Oncolytics Biotech is trading 5% up in pre-market with no confirmed catalyst

Oncolytics Biotech is trading 5.31% higher at $0.59 in pre-market on October 12, versus its October 9 close of $0.56. No reliable source directly attributes the move to a specific catalyst.

• On October 11, the company reported accelerating enrollment in its randomized REO 033 colorectal cancer study.
• Substantially all planned sites were activated, with multiple patients on study; available reporting does not establish that the update caused the pre-market gain.